Lemtrada causing ANCA-associated vasculitis adds to the growing number of autoimmune complications which can be regarded as Lemtrada side effects. Medical researchers in Switzerland recently presented the case of a 26-year-old man who developed life-threatening anti-neutrophil cytoplasmic autoantibody (ANCA) systemic vasculitis after being treated … [Read more...]
Lemtrada-Related Cardiovascular Reactions And Immune-Mediated Reactions
Lemtrada (alemtuzumab) is a monoclonal antibody (mAb) authorized for the treatment of adults with relapsing-remitting multiple sclerosis (MS). Some recent significant safety findings for this MS drug safety findings include Lemtrada cardiovascular reactions and Lemtrada immune-mediated reactions. The UK Medicines and Healthcare Products … [Read more...]
Lemtrada Safety Issues Lead To Use Restrictions In Europe
Drug safety regulators for the European Union recently recommended that Lemtrada use be restricted to certain limited patient populations due to serious side effects linked to Lemtrada. This November 5, 2019 Multiple Sclerosis News Today report, “EMA Safety Group Advises Lemtrada Be Limited to ‘Highly Active’ RRMS Patients at Hospitals … [Read more...]
Lemtrada Adverse Events: Ten Deaths Related To Lemtrada, According To New Medical Journal Article
Lemtrada adverse events (AEs) may occur more frequently than previously understood, according to an August 2019 medical journal article. This new Lemtrada drug safety information appeared in this article, “Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis”, published August 12, 2019 by BMC Research … [Read more...]
Lemtrada Drug Safety Update: Use Restrictions And Patient Monitoring For Side Effects
On May 17, 2019 the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) issued this Lemtrada Drug Safety Update, “Lemtrada (alemtuzumab) and serious cardiovascular and immune-mediated adverse reactions: new restrictions to use and strengthened monitoring requirements”, we get this summary: While an urgent [European Union (EU)] safety … [Read more...]
Lemtrada Side Effects Being Investigated By European Drug Regulatory Agency
The multiple sclerosis drug Lemtrada (alemtuzumab) is under scrutiny from the European Medicines Agency (EMA), according to the drug regulator’s April 12, 2019 press release, “Use of multiple sclerosis medicine Lemtrada restricted while EMA review is ongoing”. From this April 14, 2019 Medscape article, “PRAC Restricts Use of Alemtuzumab for MS … [Read more...]
Lemtrada: Strokes, Arterial Dissections / Blood Vessel Lining Damage
In November 2018 the FDA mandated Lemtrada label changes, which include an increased risk of strokes warning being added to the “Black-Box Warning” and a new part — 5.3 Stroke and Cervicocephalic Arterial Dissection — being added to the WARNINGS AND PRECAUTIONS section of the current Full Prescribing Information, or drug label, for … [Read more...]